Form 4: Bionano Genomics Principal Accounting Officer Reports Routine Stock Transaction for Tax Obligations

Bionano Genomics' Principal Accounting Officer, Mark Adamchak, reported the disposition of 7 shares of common stock valued at $3.69 per share to satisfy tax withholding obligations related to the vesting of a restricted stock unit award.

Summary

• Mark Adamchak, Principal Accounting Officer of Bionano Genomics, Inc. (BNGO), reported a transaction on June 3, 2025.
• The transaction involved the disposition of 7 shares of Bionano Genomics common stock.
• These shares were withheld by the Issuer at a price of $3.69 per share.
• The purpose of the withholding was to satisfy tax withholding obligations upon the settlement of a Restricted Stock Unit (RSU) award that vested on June 3, 2025.
• The RSU award was originally granted on June 3, 2024.
• Following this transaction, Mr. Adamchak directly beneficially owns 263 shares of Bionano Genomics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine administrative transaction for tax purposes related to executive compensation, with no direct operational or financial implications for the company's performance.

Positives

• The transaction indicates the vesting of a Restricted Stock Unit (RSU) award for a key executive, which is a standard component of executive compensation and retention.
• The disposition of shares was for tax withholding purposes, a routine administrative event associated with RSU vesting, rather than a discretionary sale by the officer.

Negatives

• The disposition of shares, while for tax purposes, slightly reduces the direct beneficial ownership of the reporting person in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitive landscape. It reflects standard executive compensation practices within the biotechnology or genomics sector.

Comparison to Industry Standards

• The withholding of shares for tax obligations upon RSU vesting is a common and standard practice across publicly traded companies, including those in the biotechnology and life sciences industries, such as Illumina (ILMN) or Pacific Biosciences of California (PACB), which also utilize RSU awards as part of their compensation structures.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine administrative transaction for tax purposes and does not reflect a discretionary sale or significant change in insider ownership.

Key Dates

Keywords

Bionano Genomics, BNGO, Form 4, Insider Transaction, Stock Disposition, Restricted Stock Unit, RSU, Tax Withholding, Executive Compensation, Mark Adamchak